SUPN at a glance
SUPERNUS PHARMACEUTICALS, INC. (SUPN, SEC CIK 1356576) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on August 3, 2026 and Form 4 insider filings as recently as August 14, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported revenue of $719.0 million (up 8.6% from FY2024) and a net loss of $38.5 million. Diluted EPS was -$0.68.
- As of June 30, 2026, 30 institutional investment managers tracked by SignalX reported holding SUPERNUS PHARMACEUTICALS, INC. (SUPN) shares worth $1.6 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $719.0M
- +8.6% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 30 funds
- $1.6B · +0 vs prior quarter
- Latest 8-K
- Aug 3, 2026
- Item 5.02 · Item 1.01 · Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: pharmaceutical development and commercialization of prescription drugs
- New emphasis on compliance with 2025 Executive Orders targeting drug price transparency, expanded Medicare negotiations, and site-neutral payment policies
- Strategic shift toward adapting to Most Favored Nation pricing model aligning U.S. drug prices with lowest prices in developed countries
- Healthcare cost containment policies expected to create pricing pressure and reimbursement reductions in 2026
- Significant regulatory risk from government efforts to accelerate generics/biosimilars and import lower-cost medicines
Risk Factors
- Legal risk from potential claims or fines related to 2021 ransomware attack, fines or costs not yet estimable
- Operational risk from increased ongoing IT security investments initiated post-2021 ransomware incident
- Cybersecurity vulnerability persists despite enhanced security measures and possibly inadequate insurance coverage
Management Discussion & Analysis
- Total revenues $718.95M, up 9% YoY from $661.82M driven by Qelbree $304.65M (+26%) and new launch ONAPGO $17.25M
- Operating loss driven by SG&A $485.56M (51% increase YoY) and intangible amortization $89.46M (+15%); net loss ($38.55M) vs net income $73.87M in 2024
- Best segment: Qelbree net sales $304.65M (+$63.38M, +26%), worst: Oxtellar XR $40.7M (-$58.76M, -59%) impacted by generic erosion
- Cash flow: Operating cash flow $47.33M (down $124.62M YoY), investing cash flow +$4.1M improvement due to acquisition funding, financing flows $9.13M; cash and equivalents $128.45M, marketable securities $180.22M
- Forward outlook: supplier constraints on ONAPGO impacting supply, regulatory approval risks for suppliers, expectation of variability in profits due to competitive pressures and patent expirations
AI summary of the SUPN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $219.1M, up 32% YoY from $165.5M, driven by ZURZUVAE collaboration revenue of $35.4M
- Best product performer: ONAPGO sales $13.5M, up 745% YoY; worst: Other sales $1.9M, down 71%
- Qelbree sales $89.2M, up 15% YoY; GOCOVRI sales $37.5M, up 2%
- Near-term headwind: ONAPGO supplier constraints; second supplier expected in 2027 pending FDA approval
- SPN-443 Phase 1 SAD and MAD studies planned for the second half of 2026
Risk Factors
- No material changes stated from the 2025 Form 10-K or June 30, 2026 Form 10-Q
- Business and financial-condition risk from adverse events potentially reducing common-stock market value
- Acquisition-related execution risk following April 1, 2026 Navitor asset purchase agreement
- Insider-trading compliance exposure from director’s June 15, 2026 Rule 10b5-1 plan covering 5,000 sales
AI summary of the SUPN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CEO Jack Khattar retained post-merger as President, CEO, and board member of the combined company
- Employment agreement contingent on merger closing; void if merger fails
Item 1.01: Entry into a Material Definitive Agreement
- Merger-of-equals with Indivior; Supernus shareholders receive 1.5401 Indivior shares per SUPN share
- Post-closing ownership split: Indivior holders 56.5%, Supernus holders 43.5%; SUPN ticker expected to continue on Nasdaq
Item EX-99.1: Item EX-99.1
- Proposed tax-free all-stock merger creates a CNS company with approximately $2.2B combined annual revenue and 11 commercial medicines
- Expected annual cost synergies of $125M support projected adjusted EBITDA of $888M, though savings and integration benefits remain unproven
Item 8.01: Other Events
- Supernus and Indivior executed a merger agreement for a proposed merger of equals
- Transaction remains subject to stockholder, regulatory, and other closing approvals
Item 2.02: Results of Operations and Financial Condition
- Filing contains only signature information dated August 3, 2026
- No earnings figures or operating results presented in the provided Item 2.02 text
Item EX-99.1: Item EX-99.1
- Q2 revenue $219.1M, up 32%; growth products revenue $175.7M, up 52%, led by Qelbree, ZURZUVAE, GOCOVRI, and ONAPGO
- Qelbree sales $89.2M, up 15%; prescriptions rose 17%, including 25% adult growth
Item 8.01: Other Events
- Proposed merger-of-equals with Indivior remains pending, with investor presentation scheduled for August 3, 2026
- Indivior plans Form S-4 filing containing the joint proxy statement/prospectus required for shareholder voting
Item EX-99.1: Item EX-99.1
- Proposed stock-for-stock merger of equals with Indivior, targeted to close in Q4 2026 pending shareholder and regulatory approvals
- Supernus shareholders receive 1.5401 Indivior shares per share, owning 43.5% of the combined company
AI summaries of SUPN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SUPN
Don't miss the next SUPN filing
- Alerts as it files. A push when SUPN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SUPN, by share count.
- Ask anything. An AI agent that reads every SUPN filing and answers with sources.
SUPN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Mottola Frank | M | Aug 12, 2026 | 1,650 | - |
| Rubin Jonathan | F | Aug 12, 2026 | 363 | $46.57 |
| Rubin Jonathan | M | Aug 12, 2026 | 750 | - |
| Mottola Frank | F | Aug 12, 2026 | 797 | $46.57 |
| DEC TIMOTHY C | M | Aug 12, 2026 | 1,250 | - |
| Rubin Jonathan | M | Aug 12, 2026 | 750 | - |
| DEC TIMOTHY C | M | Aug 12, 2026 | 1,250 | - |
| DEC TIMOTHY C | F | Aug 12, 2026 | 604 | $46.57 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $661.8M | $719.0M |
| Operating Income | - | $81.7M | -$62.3M |
| Net Income | $1.3M | $73.9M | -$38.5M |
| Op. Margin | - | 12.3% | -8.7% |
| Net Margin | - | 11.2% | -5.4% |
| Balance Sheet | |||
| Total Assets | - | $1.4B | $1.5B |
| Equity | $921.5M | $1.0B | $1.1B |
| ROE | 0.1% | 7.1% | -3.6% |
| Per Share | |||
| EPS | $0.02 | $1.32 | $-0.68 |
| Cash Flow | |||
| Operating CF | $111.1M | $172.0M | $47.3M |
| CapEx | - | $725K | $1.3M |
Source: XBRL data in SUPERNUS PHARMACEUTICALS, INC. (SUPN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate SUPN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 30 | $1.58B |
| Q1 2026 | 30 | $1.65B |
| Q4 2025 | 28 | $1.52B |
| Q3 2025 | 28 | $1.46B |
| Q2 2025 | 29 | $893.4M |
| Q1 2025 | 25 | $619.6M |
| Q4 2024 | 22 | $593.3M |
| Q3 2024 | 19 | $316.8M |
- Two Sigma Investments+913.1K (+337%)
- BlackRock+552.8K (+6%)
- Millennium Management+537.2K (+16%)
- State Street Corp+171.7K (+8%)
- D.E. Shaw & Co+145.2K (+23%)
- Dimensional Fund Advisors−228.9K (-10%)
- Renaissance Technologies LLC−227.0K (-13%)
- Citadel Advisors LLC−119.5K (-8%)
- Bank of America Corp−93.1K (-13%)
- Citigroup−37.3K (-50%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 211 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SUPN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 4 | Jul 31, 2026 | - | - | - |
| 4 | Jul 31, 2026 | - | - | - |
| 4 | Jul 31, 2026 | - | - | - |
| 4 | Jul 31, 2026 | - | - | - |
| 4 | Jul 31, 2026 | - | - | - |
| 8-K | Jul 22, 2026 | - | Analysis | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 8-K | May 20, 2026 | - | Analysis | |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
| SC 13G | Apr 30, 2026 | - | - | |
| SC 13G | Apr 29, 2026 | - | - | |
| 8-K | Apr 22, 2026 | - | Analysis | - |
| 8-K | Apr 7, 2026 | - | Analysis | - |
| 4 | Mar 18, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
SUPN SEC filings: frequently asked questions
Which institutions hold SUPN stock?
As of June 30, 2026, the largest SUPERNUS PHARMACEUTICALS, INC. (SUPN) holders among the 13F filers tracked by SignalX were BlackRock ($434.9 million), Millennium Management ($179.2 million), Vanguard Portfolio Management LLC ($153.7 million), Vanguard Capital Management LLC ($117.1 million), State Street Corp ($114.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SUPN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported revenue of $719.0 million (up 8.6% from FY2024) and a net loss of $38.5 million. Diluted EPS was -$0.68. The figures come from the XBRL data in the 10-K.
What are the main risks in SUPN's latest 10-K?
In the 10-K filed March 2, 2026, SUPERNUS PHARMACEUTICALS, INC. (SUPN) flagged: Legal risk from potential claims or fines related to 2021 ransomware attack, fines or costs not yet estimable. Operational risk from increased ongoing IT security investments initiated post-2021 ransomware incident. (AI summary of the Risk Factors section.)
What did SUPN report in its latest 8-K?
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K on August 3, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers), Item 1.01 (Entry into a Material Definitive Agreement) and Item 8.01 (Other Events). CEO Jack Khattar retained post-merger as President, CEO, and board member of the combined company.
What are the latest SUPN SEC filings?
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on August 3, 2026 and a Form 4 insider filing on August 14, 2026.
What is SUPN's SEC CIK number?
SUPERNUS PHARMACEUTICALS, INC. (SUPN)'s SEC Central Index Key (CIK) is 1356576. EDGAR lists every SUPN filing under that number.
Ask anything about SUPN
The research agent reads SUPN's filings, financials, insider trades and 13F holders, then answers with sources.